Fig. 3From: Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in ChinaComplete clinical response rate. The number of patients achieved complete clinical response after JAKi at the follow-up visit. Sixteen patients reached complete clinical response at 6 months. Thirty-seven patients reached response in 9 months, 42 patients in 12 months, and 44 patients in 18 months. In total, 44 refractory patients reached a responseBack to article page